Aquestive Therapeutics Files 8-K on Financials

Ticker: AQST · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1398733

Aquestive Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAquestive Therapeutics, Inc. (AQST)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.001, $70 million
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, results-of-operations, sec-filing

Related Tickers: AQST

TL;DR

AQST filed an 8-K on Jan 13, 2025, covering financials and operations.

AI Summary

Aquestive Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company, formerly known as MonoSol Rx, Inc., is incorporated in Delaware and headquartered in Warren, NJ.

Why It Matters

This 8-K filing provides crucial updates on Aquestive Therapeutics' financial performance and operational status, which are important for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial information and does not appear to contain any immediately alarming or significant negative news.

Key Players & Entities

  • Aquestive Therapeutics, Inc. (company) — Registrant
  • MonoSol Rx, Inc. (company) — Former company name
  • January 13, 2025 (date) — Date of report
  • 30 Technology Drive Warren, NJ 07059 (location) — Principal executive offices address

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Aquestive Therapeutics, Inc.'s Results of Operations and Financial Condition, as well as provide Regulation FD Disclosures and Financial Statements and Exhibits.

When was this 8-K report filed?

This 8-K report was filed on January 13, 2025.

What was Aquestive Therapeutics, Inc.'s former company name?

Aquestive Therapeutics, Inc.'s former company name was MonoSol Rx, Inc.

Where are Aquestive Therapeutics, Inc.'s principal executive offices located?

Aquestive Therapeutics, Inc.'s principal executive offices are located at 30 Technology Drive, Warren, NJ 07059.

What is the SEC Act under which this form is filed?

This form is filed under the 1934 Act.

Filing Stats: 821 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2025-01-13 07:07:41

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I
  • $70 million — December 31, 2024, it had approximately $70 million in cash and cash equivalents. The estim

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 13, 2025, Aquestive Therapeutics, Inc. ("Aquestive or the Company") issued a press release providing an update on recent business developments and outlined key objectives for 2025 in which it reported a preliminary estimate that, as of December 31, 2024, it had approximately $70 million in cash and cash equivalents. The estimated cash and cash equivalents are preliminary and unaudited, represent management estimates as of the date of this report, are subject to the completion of the Company's year-end financial closing procedures that could result in changes to these amounts and do not present all information necessary for an understanding of the Company's financial condition or results of operation as of December 31, 2024. The actual financial results may differ materially from the preliminary estimated financial information. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 2.02 by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01

Item 7.01 Regulation FD Disclosure. Additionally, the Company is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation, given at meetings with institutional investors, analysts and others. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means. A copy of the Company's investor presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The investor presentation is available on the Events and Presentations page in the Investors section of the Company's website located at www.aquestive.com, although the Company reserves the right to discontinue that availability at any time. The information in this Item 7.01 (including Exhibit 99.2) shall not be deemed to be "filed" for purposes of, or otherwise subject to the liabilities of, the Exchange Act, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d)Exhibits. Exhibit Number Description 99.1 Aquestive Therapeutics, Inc. Press Release, dated January 13, 2025 99.2 Aquestive Therapeutics, Inc. Corporate Presentation, dated January 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 13, 2025 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.